BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/27/2025 2:50:53 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-09-17 07:45 |
|
Peer-Review Started |
|
2025-09-17 07:51 |
|
First Decision by Editorial Office Director |
|
2025-10-13 09:31 |
|
Return for Revision |
|
2025-10-13 09:31 |
|
Revised |
|
2025-10-15 02:33 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-12 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-12 10:16 |
|
Articles in Press |
|
2025-11-12 10:16 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-16 01:41 |
|
Publish the Manuscript Online |
|
2025-12-27 02:50 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Justin Kritzinger, Ivanna Candel, Gynter Kotrri, Huzaifa Nadeem, Waqqas Afif, Alain Bitton, Gary Wild, Talat Bessissow and Peter Laszlo Lakatos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Peter Laszlo Lakatos, PhD, Professor, Division of Gastroenterology and Hepatology, McGill University, 1650 Avenue Cedar, Montreal H3A0G4, Quebec, Canada. kislakpet99@gmail.com |
| Key Words |
Biosimilar; Inflammatory bowel disease; Ustekinumab; Efficacy; Drug sustainability |
| Core Tip |
Switching from expensive originator biologics to lower-cost biosimilars can help reduce healthcare costs, but safety and effectiveness must be proven. This is the first real-world study of ustekinumab biosimilars in inflammatory bowel disease that showed stable disease control, unchanged biomarkers, and high treatment persistence, even in patients with prior biologic use and dose intensification. Fewer than 5% discontinued therapy, and no new safety issues emerged. These findings provide reassurance that biosimilars are a safe and effective alternative, supporting their wider adoption in clinical practice while ensuring patient outcomes remain uncompromised. |
| Publish Date |
2025-12-27 02:50 |
| Citation |
Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL. Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol 2025; 31(48): 114355 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i48/114355.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i48.114355 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
